A controlled trial to study effect of Proprioceptive Neuromuscular Facilitation exercises on improving Lower limb sensorimotor function, balance and quality of life in chemotherapy induced peripheral neuropathy in gynecological cancer
- Conditions
- Health Condition 1: G652- Sequelae of toxic polyneuropathy
- Registration Number
- CTRI/2023/03/050705
- Lead Sponsor
- Datta Meghe Institute of Higher Education and Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1)Newly diagnosed patient with stages I to III gynecologic cancers including ovarian, uterine, and cervical cancer planning to receive definitive number of platinum based compounds chemotherapy.
2)Patients who are given Taxanes and Platinum based compounds â?? Cisplastin, Carboplatin and Oxaliplatin
3)Patients having Grade I or II peripheral neuropathy according to National Cancer Institute â??common toxicity criteria
4)Planned to receive a minimum of 4 cycles of chemotherapy treatment with either of the chemotherapy agents (Platinum based compound)
5)Women between 50 to 70 years.
1)Male Patient
2)Patients having Pre existing peripheral nerve injury.
3)Patient with Type 2 Diabetes Mellitus ,Autoimmune and Inflammatory disorders
4)Patient having Grade III, IV, V peripheral neuropathy according to National Cancer Institute â?? common toxicity criteria suggesting that patient requiring assistive device are excluded.
5)Previous exposure to any of the implicated chemotherapy agents within last 5 years that could potentially cause peripheral neuropathy.
6)Stage IV cancer
7)Patients having any metal implants.
8)Patients with Artificial Pacemaker.
9)Patient having any traumatic Injury to the lower limb.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1)Shortened and Revised Total Peripheral Neuropathy Scale <br/ ><br>2)Berg Balance Scale <br/ ><br>3)Functional Assessment of Cancer Therapy/Gynecologic Oncology Group â?? Neurotoxicity Questionnaire <br/ ><br>Timepoint: Outcome Measure Will be assessed after 8 weeks of protocol and follow up will be taken after 3 weeks of completion of Intervention
- Secondary Outcome Measures
Name Time Method 1)Visual Analog Scale <br/ ><br>2)Semmes Weinstein Monofilament test <br/ ><br>Timepoint: Outcome Measure Will be assessed after 8 weeks of protocol and follow up will be taken after 3 weeks of completion of Intervention